tradingkey.logo
tradingkey.logo
검색

Anika Therapeutics Inc

ANIK
관심 목록에 추가
14.620USD
-0.110-0.75%
종가 06/25, 16:00ET시세는 15분 지연됩니다
194.53M시가총액
손실P/E TTM

Anika Therapeutics Inc

14.620
-0.110-0.75%

자세한 내용은 Anika Therapeutics Inc 회사

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Anika Therapeutics Inc 정보

종목 코드 ANIK
회사 이름Anika Therapeutics Inc
상장일May 16, 1985
CEOBlanchard (Cheryl Renee)
직원 수288
유형Ordinary Share
회계 연도 종료May 16
주소32 Wiggins Ave
도시BEDFORD
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호01730-2315
전화17814579000
웹사이트https://anika.com/
종목 코드 ANIK
상장일May 16, 1985
CEOBlanchard (Cheryl Renee)

Anika Therapeutics Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
42.57K
+6.40%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Susan L. N. Vogt
Ms. Susan L. N. Vogt
Independent Director
Independent Director
--
--
Mr. David B. Colleran, J.D.
Mr. David B. Colleran, J.D.
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
--
--
Mr. John Bell (Jack) Henneman, III
Mr. John Bell (Jack) Henneman, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Stephen O. Richard
Mr. Stephen O. Richard
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Stephen D. (Steve) Griffin
Mr. Stephen D. (Steve) Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
90.25K
+10.05%
Dr. Glenn R. Larsen, Ph.D.
Dr. Glenn R. Larsen, Ph.D.
Independent Director
Independent Director
50.26K
--
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
42.57K
+6.40%
Mr. William R. (Bill) Jellison
Mr. William R. (Bill) Jellison
Independent Director
Independent Director
23.10K
--
Mr. Joseph H. (Joe) Capper
Mr. Joseph H. (Joe) Capper
Independent Director
Independent Director
20.40K
--
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

자주 묻는 질문

Anika Therapeutics Inc의 상위 5대 주주는 누구인가요?

Anika Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Mr. Stephen D. (Steve) Griffin

Anika Therapeutics Inc(ANIK)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, Anika Therapeutics Inc의 주식을 보유한 기관은 총 264곳이며, 이들이 보유한 주식의 총 가치는 약 12.85M로 전체 발행 주식의 96.55%를 차지합니다. 이는 2025Q4 대비 -1611291.00 증가한 수치입니다.

Anika Therapeutics Inc의 최대 수익원은 무엇인가요?

2026Q1 기준, Anika Therapeutics Inc의 OEM Channel 부문이 가장 높은 매출을 기록했으며, 금액은 64.41M로 전체 매출의 57.09%를 차지했습니다.
KeyAI